Cornelissen Robin, Lievense Lysanne A, Maat Alexander P, Hendriks Rudi W, Hoogsteden Henk C, Bogers Ad J, Hegmans Joost P, Aerts Joachim G
Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Department of Cardio-Thoracic Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
PLoS One. 2014 Sep 5;9(9):e106742. doi: 10.1371/journal.pone.0106742. eCollection 2014.
The tumor micro-environment and especially the different macrophage phenotypes appear to be of great influence on the behavior of multiple tumor types. M1 skewed macrophages possess anti-tumoral capacities, while the M2 polarized macrophages have pro-tumoral capacities. We analyzed if the macrophage count and the M2 to total macrophage ratio is a discriminative marker for outcome after surgery in malignant pleural mesothelioma (MPM) and studied the prognostic value of these immunological cells.
8 MPM patients who received induction chemotherapy and surgical treatment were matched on age, sex, tumor histology, TNM stage and EORTC score with 8 patients who received chemotherapy only. CD8 positive T-cells and the total macrophage count, using the CD68 pan-macrophage marker, and CD163 positive M2 macrophage count were determined in tumor specimens prior to treatment.
The number of CD68 and CD163 cells was comparable between the surgery and the non-surgery group, and was not related to overall survival (OS) in both the surgery and non-surgery group. However, the CD163/CD68 ratio did correlate with OS in both in the total patient group (Pearson r -0.72, p<0.05). No correlation between the number of CD8 cells and prognosis was found.
The total number of macrophages in tumor tissue did not correlate with OS in both groups, however, the CD163/CD68 ratio correlates with OS in the total patient group. Our data revealed that the CD163/CD68 ratio is a potential prognostic marker in epithelioid mesothelioma patients independent of treatment but cannot be used as a predictive marker for outcome after surgery.
肿瘤微环境，尤其是不同的巨噬细胞表型，似乎对多种肿瘤类型的行为有很大影响。M1 型巨噬细胞具有抗肿瘤能力，而 M2 型极化巨噬细胞具有促肿瘤能力。我们分析了巨噬细胞计数以及 M2 型巨噬细胞与总巨噬细胞的比例是否是恶性胸膜间皮瘤（MPM）手术后预后的判别标志物，并研究了这些免疫细胞的预后价值。
8 例接受诱导化疗和手术治疗的 MPM 患者在年龄、性别、肿瘤组织学、TNM 分期和欧洲癌症研究与治疗组织（EORTC）评分方面与 8 例仅接受化疗的患者进行匹配。在治疗前，使用 CD68 全巨噬细胞标志物测定肿瘤标本中的 CD8 阳性 T 细胞、总巨噬细胞计数以及 CD163 阳性 M2 巨噬细胞计数。
手术组和非手术组之间 CD68 和 CD163 细胞数量相当，且在手术组和非手术组中均与总生存期（OS）无关。然而，CD163/CD68 比值在总患者组中与 OS 相关（Pearson 相关系数 r = -0.72，p<0.05）。未发现 CD8 细胞数量与预后之间存在相关性。
两组肿瘤组织中巨噬细胞总数均与 OS 无关，但 CD163/CD68 比值在总患者组中与 OS 相关。我们的数据表明，CD163/CD68 比值是上皮样间皮瘤患者独立于治疗的潜在预后标志物，但不能用作手术后预后的预测标志物。
